ValenzaBio

ValenzaBio is a private biopharmaceutical company dedicated to developing therapies for autoimmune and inflammatory diseases. Through a series of differentiated monoclonal antibodies targeting clinically validated mechanisms of action, we aim to provide better treatment options for patients with limited therapeutic choices. ValenzaBio strives to collaborate with all stakeholders while keeping our R&D efforts focused on the needs of patients. ValenzaBio's pipeline includes monoclonal antibodies targeting cell surface receptors. Upon binding, our drugs can reduce the activation of pathogenic responses in autoimmune and inflammatory conditions.